Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCH442416
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intravenous (for Pet Tracer And Preclinical Use), Oral (used In Animal Models)
01
Overview
SCH442416 is a highly selective small molecule antagonist of the adenosine A2A receptor (A2AR), first developed by Schering-Plough. It has been used extensively as a research tool to study the role of A2A receptors in the brain, particularly in the striatum, and has shown functional effects in preclinical models related to Parkinson’s disease, motor activity, and neuroprotection. SCH442416 is also notable as a radioligand (labeled with carbon-11: 11C-SCH442416) for positron emission tomography (PET) imaging of A2A receptor distribution and occupancy in the human and animal brain. The compound demonstrates high selectivity for the postsynaptic striatal A2A receptor subpopulation not forming heteromers with dopamine D2 receptors[3][5][6].
- Other names
- SCH442416SCH-442416SCH 442416
02
Targets
ADORA2A (Adenosine A₂A Receptor)
Beyond the preview
Go deeper on SCH442416.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCH442416.